Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.97% of ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley reduced their Q1 2025 earnings per share estimates for shares of Onsemi in a report released on Friday, January 24th ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

B. Riley analyst Zach Cummins downgraded Logility (LGTY) to Neutral from Buy with a $14.30 price target after Aptean, Insight Partners, ...

B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...

I have covered B. Riley Financial, Inc. or "B. Riley" (NASDAQ:RILY, NASDAQ:RILYL, NASDAQ:RILYP, NASDAQ:RILYM, NASDAQ:RILYK, NASDAQ:RILYN, NASDAQ:RILYG, NASDAQ:RILYT ...

LOS ANGELES, Jan. 21, 2025 /PRNewswire/ -- B. Riley Financial, Inc. (NASDAQ: RILY) ("B. Riley" or the "Company"), a diversified financial services company, today ...